Remodulin vs Uptravi
Side-by-side cost comparison based on Medicare Part D data
Remodulin
Treprostinil (SC/IV)
Manufactured by United Therapeutics
Uptravi
Selexipag
Manufactured by Janssen
Uptravi costs 38% less per claim than Remodulin ($12,882.00 vs $20,857.00). A generic version of Uptravi is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Remodulin | Uptravi |
|---|---|---|
| Avg Cost Per Claim | $20,857.00 | $12,882.00 |
| Total Medicare Spending | $876.0M | $876.0M |
| Total Beneficiaries | 4,800 | 6,800 |
| Total Claims | 42,000 | 68,000 |
| Annual Cost/Patient | $182,500.00 | $128,824.00 |
| Year-over-Year Change | +8.6% | +12.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | United Therapeutics | Janssen |
| Condition | Pulmonary Hypertension | Pulmonary Hypertension |
| Generic Name | Treprostinil (SC/IV) | Selexipag |
Remodulin vs Uptravi: What the Data Shows
Remodulin (Treprostinil (SC/IV)) and Uptravi (Selexipag) are both used to treat pulmonary hypertension. Based on Medicare Part D data, Uptravi costs $12,882.00 per claim, which is 38% less than Remodulin at $20,857.00 per claim.
Medicare spent $876.0M on Remodulin and $876.0M on Uptravi. In terms of patient reach, Uptravi serves more beneficiaries (6,800 vs 4,800).
Year-over-year spending changed +8.6% for Remodulin and +12.6% for Uptravi. Uptravi saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Uptravi is cheaper at $12,882.00 per claim, compared to $20,857.00 for Remodulin. That makes Uptravi about 38% less expensive per claim based on Medicare Part D data.
Yes, both Remodulin and Uptravi are used to treat pulmonary hypertension. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Treprostinil (SC/IV) and generic Selexipag can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $876.0M on Remodulin covering 4,800 beneficiaries, and $876.0M on Uptravi covering 6,800 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.